ERBB2 and breast cancer: NSABP FB-13 is a phase II, open label clinical trial, which will investigate the molecular and clinical effects on premenopausal patients with ER+/HER2− early invasive BC receiving neoadjuvant endocrine therapy including palbociclib, letrozole, and ovarian suppression.